Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy By Reuters
(Reuters) - Novo Nordisk (NYSE:) CEO Lars Jorgensen has agreed to voluntarily testify at a hearing focusing on U.S. prices for weight-loss drugs Ozempic and Wegovy, the Senate Committee on Health, Education, Labor and Pensions said on…